The global myelodysplastic syndrome treatment market is expected to grow at a 5.9% CAGR, from $2,990.8 million in 2022 to $5,614.1 million by 2032.
Myelodysplastic syndromes (MDS) are conditions that can occur when the bone marrow's blood-forming cells are damaged. This damage causes a decrease in the number of one or more types of blood cells. MDS is classified as a form of cancer....